Kbc Group Nv Halozyme Therapeutics, Inc. Transaction History

Kbc Group Nv

$36.3 Billion
Q4 2024

A detailed history of Kbc Group Nv transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 5,553 shares of HALO stock, worth $322,684. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,553

Previous 3,408 62.94%

Holding current value

$322,684

Previous $195,000 35.9%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 22, 2025	BUY	$42.57 - $61.09 $91,312 - $131,038	2,145 Added 62.94%	5,553 $265,000
Q3 2024 Nov 06, 2024	BUY	$51.3 - $64.42 $15,903 - $19,970	310 Added 10.01%	3,408 $195,000
Q2 2024 Jul 17, 2024	BUY	$37.81 - $52.4 $9,528 - $13,204	252 Added 8.85%	3,098 $162,000
Q4 2023 Feb 13, 2024	BUY	$33.32 - $42.1 $94,828 - $119,816	2,846 New	2,846 $105,000
Q3 2023 Feb 15, 2024	SELL	$36.46 - $44.03 $372,438 - $449,766	-10,215 Reduced 78.21%	2,846 $109,000
Q3 2022 Feb 15, 2024	BUY	$38.53 - $51.78 $393,583 - $528,932	10,215 Added 358.92%	13,061 $516,000
Q3 2022 Nov 08, 2022	SELL	$38.53 - $51.78 $4,662 - $6,265	-121 Reduced 0.92%	13,061 $516,000
Q2 2022 Feb 14, 2024	BUY	$37.35 - $48.3 $329,427 - $426,006	8,820 Added 202.2%	13,182 $580,000
Q2 2022 Jul 26, 2022	BUY	$37.35 - $48.3 $329,427 - $426,006	8,820 Added 202.2%	13,182 $580,000
Q4 2021 Feb 14, 2024	BUY	$31.82 - $40.75 $48,239 - $61,777	1,516 Added 53.27%	4,362 $175,000
Q4 2021 Feb 03, 2022	BUY	$31.82 - $40.75 $138,798 - $177,751	4,362 New	4,362 $175,000

Others Institutions Holding HALO

# of Institutions

545

Shares Held

121M

Call Options Held

419K

Put Options Held

172K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.09B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account